A Retrospective Analysis of the Clinical Effectiveness of Tigecycline in the Treatment of Clostridioides difficile-Associated Diarrhea
Open Access
- 13 June 2024
- journal article
- research article
- Published by MDPI AG in Pharmacoepidemiology
- Vol. 3 (2) , 231-240
Abstract
Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea in the United States. Tigecycline has been proposed as a potential treatment for CDI, though limited clinical data exist to support this practice. The objective of this study was to determine if the provision of tigecycline provides a clinically meaningful benefit to inpatients with CDI. This study was a retrospective chart review enrolling inpatients receiving treatment for CDI. Patients were divided into cohorts depending on whether they received a standard antibiotic therapy regimen for CDI or an antibiotic treatment regimen that included tigecycline. The primary outcome was clinical recovery at the time of hospital discharge. A total of 39 and 22 patients were included in the standard antibiotic therapy and tigecycline groups, respectively. ATLAS (Age, Treatment, Leukocyte, Albumin, Serum creatinine) scores at the time of CDI diagnosis were similar between the two groups, though patients in the tigecycline groups were more likely to represent a recurrent episode of CDI. There was no difference in the rate of clinical recovery at the time of hospital discharge between the standard antibiotic therapy and tigecycline groups (38.5% vs. 36.4%, p = 0.8710). These data do not support the routine use of tigecycline for the treatment of CDI, though interpretation is limited due to baseline differences between groups and the retrospective, observational nature of this study.Keywords
This publication has 30 references indexed in Scilit:
- European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adultsClinical Microbiology and Infection, 2021
- Severe Clostridium difficile infections in intensive care units: Diverse clinical presentationsJournal of Microbiology, Immunology and Infection, 2021
- Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidenceEuropean Journal of Clinical Microbiology & Infectious Diseases, 2020
- The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort studyClinical Microbiology and Infection, 2017
- Use of tigecycline for the management of Clostridium difficile colitis in oncology patients and case series of breakthrough infectionsJournal of Hospital Infection, 2017
- Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort studyClinical Microbiology and Infection, 2016
- Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile InfectionInfectious Diseases and Therapy, 2014
- Tigecycline for severe Clostridium difficile infectionInternational Journal of Infectious Diseases, 2014
- Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazoleInternational Journal of Antimicrobial Agents, 2010
- Fulminant Clostridium difficile ColitisArchives of Surgery, 2009